Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

An expert discusses how the diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) require careful recognition of characteristic dermatologic and hematologic features, with ...

The key takeaways are that prostate cancer misinformation is widespread across online platforms and spans many different ...

During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor ...

A phase 2 study showed that giving maintenance regorafenib could delay disease progression in patients with non-adipocytic ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Jethro C.C. Kwong, a urology resident from the University of Toronto, discusses a novel artificial intelligence (AI)-based ...